BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024
BiomX (NYSE American: PHGE), a clinical-stage company specializing in phage therapies targeting pathogenic bacteria, announced a conference call and webcast scheduled for May 21, 2024, at 8:00 a.m. ET.
The event will cover the company's first quarter 2024 financial results along with business and program updates. Participants can join the call via dedicated U.S. and international dial-in numbers, and the webcast will be accessible in the Investors section of BiomX's website.
- BiomX is providing clear communication by hosting a conference call and webcast to discuss Q1 2024 financial results and business updates on May 21, 2024.
- The announcement of the webcast and call ahead of time allows investors to prepare and participate actively.
- The company's commitment to transparency is highlighted by offering both live and archived webcasts.
- The press release lacks specific financial data or preliminary insights into the Q1 2024 results, which could create uncertainty among investors.
- No mention of upcoming milestones or specific achievements may signal a lack of significant progress or developments.
GAITHERSBURG, Maryland and NESS ZIONA, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Tuesday, May 21, 2024, at 8:00 a.m. ET, to report first quarter 2024 financial results and provide business and program updates.
To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
BiomX, Inc.
Assaf Oron
+97254-2228901
assafo@biomx.com
FAQ
When will BiomX report its first quarter 2024 financial results?
How can I participate in BiomX's Q1 2024 financial results conference call?
Where can I access the live and archived webcast of BiomX's financial results call?
What time is BiomX's Q1 2024 financial results conference call?
What will BiomX discuss in their May 21, 2024, conference call?
